D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 74 Citations 17,105 240 World Ranking 12622 National Ranking 425

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Disease

His scientific interests lie mostly in Angioedema, Hereditary angioedema, C1-inhibitor, Ecallantide and Internal medicine. His Angioedema study deals with the bigger picture of Immunology. His Hereditary angioedema research is multidisciplinary, relying on both Vaginal delivery, MEDLINE, Intensive care medicine, Alternative medicine and Disease.

His research in C1-inhibitor intersects with topics in Autoantibody, Lanadelumab and Chronic lymphocytic leukemia. His work carried out in the field of Ecallantide brings together such families of science as C1 inhibitor deficiency, Randomized controlled trial and Family medicine. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and Antigen.

His most cited work include:

  • Plasma bradykinin in angio-oedema (589 citations)
  • Hereditary and Acquired C1-inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients (512 citations)
  • Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. (499 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Hereditary angioedema, Angioedema, C1-inhibitor, Internal medicine and Immunology. His work is dedicated to discovering how Hereditary angioedema, Surgery are connected with Anesthesia and other disciplines. He has researched Angioedema in several fields, including Ecallantide, Disease, Bradykinin and Edema.

His research integrates issues of Proteases, Kallikrein, Serpin and Pharmacology in his study of C1-inhibitor. His Internal medicine research integrates issues from Gastroenterology, Placebo and Endocrinology. His work focuses on many connections between Placebo and other disciplines, such as Randomized controlled trial, that overlap with his field of interest in Clinical trial.

He most often published in these fields:

  • Hereditary angioedema (57.43%)
  • Angioedema (38.57%)
  • C1-inhibitor (33.14%)

What were the highlights of his more recent work (between 2016-2021)?

  • Hereditary angioedema (57.43%)
  • C1-inhibitor (33.14%)
  • Angioedema (38.57%)

In recent papers he was focusing on the following fields of study:

Marco Cicardi focuses on Hereditary angioedema, C1-inhibitor, Angioedema, Internal medicine and Dermatology. In his works, Marco Cicardi undertakes multidisciplinary study on Hereditary angioedema and In patient. His study on C1-inhibitor is covered under Immunology.

His work on C1 inhibitor deficiency and Complement system as part of general Immunology research is often related to Functional activity and Contact system, thus linking different fields of science. His Angioedema research focuses on Bradykinin and how it connects with Kallikrein and ACE inhibitor. His Internal medicine research incorporates elements of Gastroenterology, Placebo, Endocrinology and Cardiology.

Between 2016 and 2021, his most popular works were:

  • Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema (128 citations)
  • Inhibiting plasma kallikrein for hereditary angioedema prophylaxis (85 citations)
  • Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor (82 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Disease

His primary areas of investigation include Hereditary angioedema, C1-inhibitor, Angioedema, Internal medicine and Bradykinin. His Hereditary angioedema research includes themes of Adverse effect, Pharmacology, Kallikrein and Disease, Rare disease. The concepts of his C1-inhibitor study are interwoven with issues in Autonomic nervous system, Pharmacokinetics, Gene and Pediatrics.

Angioedema is the subject of his research, which falls under Dermatology. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Placebo. His work deals with themes such as Adrenomedullin, Endocrinology and ACE inhibitor, which intersect with Bradykinin.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Plasma bradykinin in angio-oedema

Juerg Nussberger;Massimo Cugno;Catherine Amstutz;Marco Cicardi.
The Lancet (1998)

784 Citations

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Angelo Agostoni;Emel Aygören-Pürsün;Karen E. Binkley;Alvaro Blanch.
The Journal of Allergy and Clinical Immunology (2004)

780 Citations

Hereditary and Acquired C1-inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients

Angelo Agostoni;Marco Cicardi.
Medicine (1992)

750 Citations

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Tom Bowen;Marco Cicardi;Henriette Farkas;Konrad Bork.
Allergy, Asthma & Clinical Immunology (2004)

581 Citations

Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group

Marco Cicardi;W. Aberer;A. Banerji;M. Bas.
Allergy (2014)

549 Citations

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Marco Cicardi;Aleena Banerji;Francisco Bracho;Alejandro Malbrán.
The New England Journal of Medicine (2010)

540 Citations

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group

M. Cicardi;K. Bork;T. Caballero;T. Craig.
Allergy (2012)

409 Citations

Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema

Marco Cicardi;Robyn J. Levy;Donald L. McNeil;H. Henry Li.
The New England Journal of Medicine (2010)

329 Citations

Hereditary angio-oedema

Hilary Longhurst;Marco Cicardi.
The Lancet (2012)

314 Citations

C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.

Massimo Cugno;Andrea Zanichelli;Fabrizio Foieni;Sonia Caccia.
Trends in Molecular Medicine (2009)

299 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Marco Cicardi

Timothy J. Craig

Timothy J. Craig

Pennsylvania State University

Publications: 71

Jonathan A. Bernstein

Jonathan A. Bernstein

Stanford University

Publications: 69

Marcus Maurer

Marcus Maurer

Charité - University Medicine Berlin

Publications: 60

Olivier Fain

Olivier Fain

Université Paris Cité

Publications: 40

Massimo Cugno

Massimo Cugno

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Publications: 36

Michael M. Frank

Michael M. Frank

Duke University

Publications: 34

George Füst

George Füst

Semmelweis University

Publications: 32

Thomas Renné

Thomas Renné

Universität Hamburg

Publications: 30

Werner Aberer

Werner Aberer

University of Graz

Publications: 26

Michael Kirschfink

Michael Kirschfink

Heidelberg University

Publications: 18

Sven Cichon

Sven Cichon

University Hospital of Basel

Publications: 16

Berhane Ghebrehiwet

Berhane Ghebrehiwet

Stony Brook University

Publications: 16

Tom Eirik Mollnes

Tom Eirik Mollnes

Oslo University Hospital

Publications: 16

Marcel Levi

Marcel Levi

University College London Hospitals NHS Foundation Trust

Publications: 15

François Marceau

François Marceau

Université Laval

Publications: 14

Nancy J. Brown

Nancy J. Brown

Vanderbilt University Medical Center

Publications: 13

Something went wrong. Please try again later.